Drug Trial Radar · NCT07681089
A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
7
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Nov 30, 2027
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Kiminori Kimura, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Japan Agency for Medical Research and Development; Ohara Pharmaceutical Co., Ltd.
- First posted
- Jul 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.
Conditions
- Liver Cirrhosis
Interventions
FoscenvivintDrug
Experimental:Foscenvivint Administered by intravenous (IV) infusion over 3-4 hours Arm Description:Foscenvivint 280 mg/m2, once a week for 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- ALBI scoreTime frame: Baseline to 24 weeks after administration
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Hokkaido University Hospital
Sapporo, Hokkaido, Japan · Recruiting
National Hospital Organization Sendai Medical Center
Sendai, Miyagi, Japan · Recruiting
National Hospital Organization Osaka National Hospital
Osaka, Osaka, Japan · Recruiting
Tokyo Metropolitan Komagome Hospital
Bunkyo-Ku, Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.